drugset / Trial / NCT07579936
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
Phase 2
Recruiting
200 enrolled
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Salubris (Suzhou) Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, open-label, parallel-controlled Phase II study designed to evaluate the differences in safety among four different dosing regimens of SAL056.
Timeline
- Start
- 2026-04-30
- Primary completion
- 2026-07-30
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SAL056 | Protein / enzyme biologic | 28.2 ug | — |
| Subject | SAL056 | Protein / enzyme biologic | 56.5 ug | — |
| Subject | Teriparatide | Protein / enzyme biologic | — | — |